TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF THE GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET 13
1.4 LIMITATIONS 14
1.5 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 18
2.4 CURRENCY AND PRICING 18
2.5 DBMR TRIPOD DATA VALIDATION MODEL 19
2.6 MULTIVARIATE MODELLING 22
2.7 PRODUCTS LIFELINE CURVE 22
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23
2.9 DBMR MARKET POSITION GRID 24
2.10 MARKET END USER COVERAGE GRID 25
2.11 VENDOR SHARE ANALYSIS 26
2.12 SECONDARY SOURCES 27
2.13 ASSUMPTIONS 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 32
4.1 PESTEL ANALYSIS 33
4.2 PORTERS FIVE FORCES 34
5 REGULATORY FRAMEWORK 35
5.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) 35
5.2 REGULATORY FRAMEWORK FOR ECOA 35
5.3 ICH E6 (R2) 35
5.4 FDA GUIDANCE 35
5.5 EMA GUIDELINES 35
5.5.1 ISO 14155 36
5.5.2 PRIVACY REGULATIONS 36
6 MARKET OVERVIEW 37
6.1 DRIVERS 39
6.1.1 GROWING ACCEPTANCE OF ECOA AMONG CLINICAL RESEARCH PROFESSIONALS 39
6.1.2 PARADIGM SHIFT TOWARDS ELECTRONIC DATA CAPTURING FROM PAPER-BASED PROCEDURES 40
6.1.3 GOVERNMENT INITIATIVES ABOUT THE ADOPTION OF ECLINICAL PLATFORMS 41
6.2 RESTRAINTS 41
6.2.1 IMPLEMENTATION OF BRING YOUR OWN DEVICE (BYOD) TECHNOLOGY IN CLINICAL TRIALS 41
6.2.2 LACK OF PROPER HEALTHCARE IT INFRASTRUCTURE IN DEVELOPING COUNTRIES 42
6.3 OPPORTUNITIES 44
6.3.1 GROWING ADOPTION OF CLOUD BASED SERVICES 44
6.3.2 RISING NUMBER OF RESEARCH STUDIES FOCUSING ON CLINICAL OUTCOME ASSESSMENTS 44
6.4 CHALLENGES 45
6.4.1 DIFFICULTIES ASSOCIATED WITH TRAINING OF RESPONDENTS TO FILL ELECTRONIC QUESTIONNAIRES 45
6.4.2 STREAMLINING OF ECOA SERVICES 45
7 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY TYPE 47
7.1 OVERVIEW 48
7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) 51
7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO) 51
7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) 51
7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO) 51
8 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY MODALITY 52
8.1 OVERVIEW 53
8.2 SITE-BASED SOLUTIONS 56
8.3 WEB SOLUTIONS 56
8.4 HANDHELD 56
8.4.1 BRING-YOUR-OWN-DEVICE (BYOD) 56
8.4.2 PROVISIONED DEVICES 56
9 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY END USER 57
9.1 OVERVIEW 58
9.2 CONTRACT RESEARCH ORGANIZATIONS (CROS) 61
9.3 PHARMACEUTICAL AND BIOTECHNOLOGY FIRMS 61
9.4 MEDICAL DEVICE COMPANIES 61
9.5 HOSPITALS/HEALTHCARE PROVIDERS 61
9.6 CONSULTING SERVICE COMPANIES 61
9.7 ACADEMIC & RESEARCH INSTITUTES 61
9.8 OTHERS 61
10 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY DELIVERY MODE 62
10.1 OVERVIEW 63
10.2 CLOUD-BASED 66
10.3 WEB-HOSTED 66
11 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET BY GEOGRAPHY 67
11.1 OVERVIEW 67
11.2 NORTH AMERICA 69
11.2.1 U.S. 69
11.2.2 CANADA 69
11.2.3 MEXICO 69
11.3 EUROPE 70
11.3.1 U.K. 70
11.3.2 GERMANY 70
11.3.3 SPAIN 70
11.3.4 FRANCE 70
11.3.5 ITALY 70
11.3.6 SWITZERLAND 70
11.3.7 NETHERLANDS 70
11.3.8 BELGIUM 71
11.3.9 TURKEY 71
11.3.10 RUSSIA 71
11.3.11 REST OF EUROPE 71
11.4 ASIA-PACIFIC 72
11.4.1 CHINA 72
11.4.2 JAPAN 72
11.4.3 AUSTRALIA 72
11.4.4 SOUTH KOREA 72
11.4.5 INDIA 72
11.4.6 SINAGPORE 72
11.4.7 THAILAND 72
11.4.8 MALAYSIA 72
11.4.9 INDONESIA 73
11.4.10 PHILIPPINES 73
11.4.11 REST OF ASIA-PACIFIC 73
11.5 SOUTH AMERICA 74
11.5.1 BRAZIL 74
11.5.2 ARGENTINA 74
11.5.3 REST OF SOUTH AMERICA 74
11.6 MIDDLE EAST AND AFRICA 75
11.6.1 SOUTH AFRICA 75
11.6.2 U.A.E. 75
11.6.3 ISRAEL 75
11.6.4 SAUDI ARABIA 75
11.6.5 EGYPT 75
11.6.6 REST OF MIDDLE EAST AND AFRICA 75
12 GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, COMPANY LANDSCAPE 76
12.1 COMPANY SHARE ANALYSIS: GLOBAL 76
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 77
12.3 COMPANY SHARE ANALYSIS: EUROPE 78
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 79
13 SWOT ANALYSIS 80
14 COMPANY PROFILE 81
14.1 MEDIDATA 81
14.1.1 COMPANY SNAPSHOT 81
14.1.2 REVENUE ANALYSIS 81
14.1.3 COMPANY SHARE ANALYSIS 82
14.1.4 PRODUCT PORTFOLIO 82
14.1.5 RECENT DEVELOPMENTS 82
14.2 CLARIO 83
14.2.1 COMPANY SNAPSHOT 83
14.2.2 COMPANY SHARE ANALYSIS 83
14.2.3 PRODUCT PORTFOLIO 84
14.2.4 RECENT DEVELOPMENT 84
14.3 IBM 85
14.3.1 COMPANY SNAPSHOT 85
14.3.2 REVENUE ANALYSIS 85
14.3.3 COMPANY SHARE ANALYSIS 86
14.3.4 PRODUCT PORTFOLIO 86
14.3.5 RECENT DEVELOPMENT 86
14.4 SIGNANT HEALTH 87
14.4.1 COMPANY SNAPSHOT 87
14.4.2 COMPANY SHARE ANALYSIS 87
14.4.3 PRODUCT PORTFOLIO 88
14.4.4 RECENT DEVELOPMENTS 88
14.5 IQVIA INC, 89
14.5.1 COMPANY SNAPSHOT 89
14.5.2 REVENUE ANALYSIS 89
14.5.3 COMPANY SHARE ANALYSIS 90
14.5.4 PRODUCT PORTFOLIO 90
14.5.5 RECENT DEVELOPMENT 90
14.6 ARISGLOBAL 91
14.6.1 COMPANY SNAPSHOT 91
14.6.2 PRODUCT PORTFOLIO 91
14.6.3 RECENT DEVELOPMENTS 92
14.7 CASTOR 93
14.7.1 COMPANY SNAPSHOT 93
14.7.2 PRODUCT PORTFOLIO 93
14.7.3 RECENT DEVELOPMENTS 93
14.8 CLOUDBYZ 94
14.8.1 COMPANY SNAPSHOT 94
14.8.2 PRODUCT PORTFOLIO 94
14.8.3 RECENT DEVELOPMENT 94
14.9 CLINICAL INK. 95
14.9.1 COMPANY SNAPSHOT 95
14.9.2 PRODUCT PORTFOLIO 95
14.9.3 RECENT DEVELOPMENT 95
14.10 EVIDENTIQ 96
14.10.1 COMPANY SNAPSHOT 96
14.10.2 PRODUCT PORTFOLIO 96
14.10.3 RECENT DEVELOPMENT 96
14.11 FOUNTAYN 97
14.11.1 COMPANY SNAPSHOT 97
14.11.2 PRODUCT PORTFOLIO 97
14.11.3 RECENT DEVELOPMENTS 97
14.12 KAYENTIS 98
14.12.1 COMPANY SNAPSHOT 98
14.12.2 PRODUCT PORTFOLIO 98
14.12.3 RECENT DEVELOPMENT 98
14.13 RAYLYTIC GMBH 99
14.13.1 COMPANY SNAPSHOT 99
14.13.2 PRODUCT PORTFOLIO 99
14.13.3 RECENT DEVELOPMENTS 99
14.14 TRANSPERFECT LIFE SCIENCES LIFE SCIENCES 100
14.14.1 COMPANY SNAPSHOT 100
14.14.2 PRODUCT PORTFOLIO 100
14.14.3 RECENT DEVELOPMENT 100
14.15 VITALOGRAPH 101
14.15.1 COMPANY SNAPSHOT 101
14.15.2 PRODUCT PORTFOLIO 101
14.15.3 RECENT DEVELOPMENTS 101
14.16 YPRIME LLC. 102
14.16.1 COMPANY SNAPSHOT 102
14.16.2 PRODUCT PORTFOLIO 102
14.16.3 RECENT DEVELOPMENTS 102
15 QUESTIONNAIRE 103
16 RELATED REPORTS 106

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.